EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apheresis CD8+CCR7+CD45RA− T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome

Iván García de la Torre iD, Carlota García-Hoz iD, Fernando Martin-Moro iD, José Ignacio Fernández-Velasco iD, Kyra Velázquez-Kennedy, Eulalia Rodríguez-Martín iD, Alejandro Luna De Abia iD, Ernesto Roldán, Gemma Moreno Jiménez, Javier López-Jiménez iD, Luisa María Villar iD, Roberto Pariente-Rodríguez iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27020866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Iván García de la Torre und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. Hauptthemen laut MEDLINE: Leukocyte Common Antigens, Immunotherapy, Adoptive, CD8-Positive T-Lymphocytes, Receptors, CCR7. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Ramón y Cajal de Investigación Sanitaria, FIBIO-HRC (Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal) and IRYCIS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL); however, a significant proportion of patients fail to achieve a durable response, underscoring the need for reliable predictive biomarkers. We characterize T-lymphocyte subpopulations in apheresis samples from 23 r/r large B-cell lymphoma (LBCL) patients who received axicabtagene ciloleucel (axi-cel) to identify pre-treatment cell biomarkers associated with CAR T-cell kinetics and clinical outcomes. Immunophenotyping of T-cells within fresh apheresis samples and monitoring of circulating CAR T-cells were performed by multiparametric flow cytometry. The median peak CAR T-cell count was 45.2 CAR T-cells/mL. Strong CAR-T expanders (≥45.2 CAR T-cells/mL) exhibited higher values of both CD4+ (p = 0.011) and CD8+ (p = 0.023) central memory T-cells (TCM; CCR7+CD45RA−), as well as lower proportions of CD8+CD38+ T-cells in apheresis samples. In apheresis, a cut-off value of >4.3% of CD8+ TCM predicted strong CAR-T expansion (AUC: 0.80; p = 0.023) and superior progression-free survival (p = 0.04) compared with patients who had CD8+ TCM below the cut-off. Our data suggest that high frequencies of CD8+ TCM cells in apheresis samples may represent a promising pre-treatment biomarker associated with strong CAR-T expansion and superior clinical outcome in r/r LBCL patients following axi-cel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte Common AntigensImmunotherapy, AdoptiveCD8-Positive T-LymphocytesReceptors, CCR7Lymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenHumansFemaleMaleMiddle AgedAgedBlood Component RemovalBiomarkersImmunophenotypingAdultBiomarkers, TumorBiological Products

Stichwörter der Autor:innen

CAR-Tapheresisbiomarkerscentral memory T-cellsdiffuse large B-cell lymphomaflow cytometry

Substanzen

Leukocyte Common AntigensReceptors, CCR7Receptors, Chimeric AntigenCCR7 protein, humanBiomarkersaxicabtagene ciloleucelBiomarkers, TumorBiological Products

Autor:innen und Institutionen

  • Department of Immunology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
  • Department of Hematology, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.

ORCID-Profile: Iván García de la Torre, Carlota García-Hoz, Fernando Martin-Moro, José Ignacio Fernández-Velasco, Eulalia Rodríguez-Martín, Alejandro Luna De Abia, Javier López-Jiménez, Luisa María Villar, Roberto Pariente-Rodríguez

Förderung

  • Instituto Ramón y Cajal de Investigación Sanitaria
  • FIBIO-HRC (Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal) and IRYCIS

Zitieren

APA

García de la Torre, I., García-Hoz, C., Martin-Moro, F., Fernández-Velasco, J. I., Velázquez-Kennedy, K., Rodríguez-Martín, E., Luna De Abia, A., Roldán, E., Moreno Jiménez, G., López-Jiménez, J., Villar, L. M., & Pariente-Rodríguez, R. (2026). Apheresis CD8+CCR7+CD45RA− T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020866

Vancouver

García de la Torre I, García-Hoz C, Martin-Moro F, Fernández-Velasco JI, Velázquez-Kennedy K, Rodríguez-Martín E, et al. Apheresis CD8+CCR7+CD45RA− T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020866

BibTeX
@article{GarcadelaTorre2026,
  author = {García de la Torre, Iván and García-Hoz, Carlota and Martin-Moro, Fernando and Fernández-Velasco, José Ignacio and Velázquez-Kennedy, Kyra and Rodríguez-Martín, Eulalia and Luna De Abia, Alejandro and Roldán, Ernesto and Moreno Jiménez, Gemma and López-Jiménez, Javier and Villar, Luisa María and Pariente-Rodríguez, Roberto},
  title = {Apheresis CD8+CCR7+CD45RA− T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27020866}
}
Kostenlos starten →